[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"motor-deficits\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:motor-deficits":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,73,119,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100624720","investigation-of-preoperative-factors-influencing-the-outcome-of-motor-deficits-in-patients-undergoing-lumbar-microdiskectomy-100624720",false,"NCT07413302","Investigation of Preoperative Factors Influencing the Outcome of Motor Deficits in Patients Undergoing Lumbar Microdiskectomy","Inclusion Criteria:\n\n* Patients suffering from lower limb paresis (motor deficit) caused by lumbar disk herniation undergoing a single-level microdiskectomy\n* Age (years) \\> 17\n\nExclusion Criteria:\n\n* Age (years) \\\u003C 18\n* Medical history of lumbar spine surgery\n* Absence of limb paresis\n* Motor deficit caused by other than disk herniation aetiologies\n* Reoperation within 6 months after microdiskectomy\n* Microdiskectomy at more than one level\n* Cauda equina syndrome\n* Peripheral neuropathy","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","6 Months","OBSERVATIONAL","Lumbar disc herniations may result in lower limb weakness. In such cases, there is a strong indication for surgical intervention through microdiscectomy. This clinical study aims to investigate preoperative factors that may influence the postoperative outcomes of patients undergoing this procedure.",[24,25,26,27,28],"Motor Deficits","Lumbar Discectomy","Muscle Weakness","Paresis","Lumbar Disc Herniation",[30,31,32,33,34,35],"microdiscectomy","lumbar disc herniation","motor deficit","lower limb paresis","prognostic factors microdiscectomy","disc herniation outcome","RECRUITING","2026-02-09",{"date":39,"type":40},"2026-02-17","ACTUAL",{"date":42,"type":40},"2024-07-03",{"date":44,"type":19},"2026-12",{"name":46,"class":47},"Aristotle University Of Thessaloniki","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":15,"minAge":16,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100360906","developing-effectiveness-evaluation-and-therapeutic-programs-of-rehabilitation-100360906","NCT03979235","Developing Effectiveness Evaluation and Therapeutic Programs of Rehabilitation","Developing Clinic-oriented Quantitative Effectiveness Evaluation and Individualized Therapeutic Programs of Rehabilitation","Inclusion Criteria (for healthy people):\n\n* no history of psychological\u002Fpsychotic problems, no history of important diseases.\n\nExclusion Criteria (for healthy people):\n\n* history of psychological\u002Fpsychotic problems\n\nInclusion Criteria (for patients with motor deficits or dysphagia):\n\n* patients with motor function impairment such as post stroke hemiplegia.\n\nExclusion Criteria (for patients with motor deficits or dysphagia):\n\n* cognitively or physically unable to cooperate with the examiner to finish the test",true,"80 Years",{"count":18,"type":19},"Using robotics, sensors, and sEMG to develop clinic-oriented quantitative effectiveness evaluation and individualized programs of rehabilitation",[61,24,62],"Healthy Volunteers","Dysphagia","2025-05-20",{"date":65,"type":40},"2025-05-23",{"date":67,"type":40},"2019-06-05",{"date":69,"type":19},"2026-12-31",{"name":71,"class":47},"National Research Center for Rehabilitation Technical Aids",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":98,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":72},"100588304","bci-assisted-scs-exs-for-gait-optimization-100588304","NCT06939660","BCI-Assisted SCS-EXS for Gait Optimization","Spatiotemporal Spinal Cord Stimulation Based on Implantable Brain-machine Interfaces and Exoskeletons for Spinal Cord Injury (BASEGO)","BASEGO","Inclusion Criteria:\n\n* Age 14-65 years, any gender.\n* Clinical diagnosis of spinal cord injury (SCI) due to trauma, inflammation, tumor, vascular disease, or iatrogenic factors, confirmed by medical history, physical examination, and ancillary tests, resulting in lower limb motor dysfunction.\n* SCI diagnosed ≥6 months prior, with ≥1 month of continuous conventional rehabilitation (e.g., physical therapy, acupuncture, hydrotherapy, ≥3 hours daily) without significant improvement in motor function in the past 2 months.\n* ASIA Impairment Scale (AIS) grade A, B, or C based on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).\n* Good general health with a life expectancy ≥12 months.\n* Mini-Mental State Examination (MMSE) score ≥22.\n* Educational attainment of secondary school or above.\n* Willingness to participate, provide informed consent, and comply with study follow-up.\n\nExclusion Criteria:\n\n* Presence of diseases other than spinal cord injury (SCI) that affect lower limb motor function, including brain diseases (e.g., brain tumor, stroke), lower limb vascular diseases (e.g., lower limb vascular occlusion), peripheral nerve diseases, or lower limb bone diseases (e.g., osteoarthritis, joint contracture).\n* Requires continuous medical interventions (e.g., tracheal intubation, nasogastric feeding) to maintain critical physiological functions (e.g., heartbeat, respiration, swallowing).\n* Congenital or acquired structural abnormalities of the lower limb bones or muscles.\n* Presence of surgical contraindications (e.g., anesthesia-related adverse reactions, coagulation risks, or surgeon's determination of unsuitability for surgery).\n* Presence of active implantable devices except for SCS or BCI devices (e.g., pacemakers, defibrillators, drug infusion pumps, cochlear implants, sacral nerve stimulators).\n* Unable to receive implantable devices due to other disease treatments or investigations, or requires magnetic resonance imaging (MRI) during the device implantation period.\n* MRI shows structural damage \\>50% in motor function areas (precentral and postcentral gyri, ventromedial sensorimotor areas, mid temporal lobe, Broca's area, Wernicke's area, Geschwind's area), or DTI shows damage \\>50% in the posterior limb of the internal capsule.\n* Severe cardiovascular disease: Above level II myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QTc interval ≥450 ms in men, ≥470 ms in women), level III-IV heart failure (NYHA classification), or echocardiography showing LVEF \\\u003C50%.\n* Coagulation abnormalities (INR \\>1.5 ULN, PT \\>ULN +4 s, or APTT \\>1.5 ULN), hemorrhagic tendency, or undergoing thrombolytic or anticoagulant therapy.\n* Severe infections within 4 weeks before surgery (requiring IV antibiotics, antifungals, or antivirals) or lumbar soft tissue infections, or unexplained fever \\>38.5℃ during screening or before surgery.\n* HIV infection, acquired immunodeficiency syndrome (AIDS), active tuberculosis, active hepatitis B (HBV DNA ≥500 IU\u002Fml), hepatitis C (positive HCV antibody and detectable HCV-RNA), or co-infection of hepatitis B and C.\n\nSevere cerebrovascular events (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, or pulmonary embolism within 12 months before enrollment.\n\n* Metastatic malignancies or untreated malignant tumors.\n* Major surgery or severe traumatic injuries, fractures, or ulcers within 4 weeks before enrollment.\n* Addictive habits such as drug abuse or alcoholism.\n* History of psychotropic drug abuse that is not controllable or presence of mental disorders, including major psychiatric illnesses (e.g., depression \\[BDI score \\>20\\], anxiety, obsessive-compulsive disorder, schizophrenia, autism, chronic sleep disorders, consciousness disorders).\n* Pregnant, breastfeeding, planning to conceive, or women of childbearing potential without reliable contraception.\n* Participation in other clinical trials within the past month.\n* Cognitive impairments or poor compliance from subjects, family members, or caregivers, or inability to complete at least 12 months of follow-up and rehabilitation training.\n* Other conditions that increase the risk of study participation or device use, as determined by the investigator.","14 Years","65 Years",{"count":48,"type":19},"INTERVENTIONAL",[86],"NA","The goal of this clinical trial is to evaluate the safety and technical feasibility of a novel brain-machine interface (BCI)-assisted spinal cord stimulation (SCS) and exoskeleton (EXS) system in patients with spinal cord injury (SCI). The primary aim is to determine whether the BCI-SCS-EXS system can safely and effectively improve lower limb motor function and quality of life in individuals with chronic SCI.\n\nParticipant Population:\n\nAdults aged 14-65 years (sex\u002Fgender not limited). Patients with chronic SCI (≥6 months post-injury) classified as ASIA A, B, or C.\n\nIndividuals with stable health status, MMSE ≥22, and secondary education or above.\n\nPrimary Questions:\n\n1. Is the BCI-SCS-EXS system safe and technically feasible for SCI rehabilitation?\n2. Does the system improve lower limb motor function and quality of life in SCI patients?\n\nInterventions:\n\nParticipants will undergo the following procedures:\n\nPhase I (Implantation):\n\nBCI implantation: ECoG electrodes placed over the motor cortex to decode lower limb movement intent.\n\nSCS electrode implantation: 5-6-5 paddle electrodes at T11-L2 for targeted spinal cord stimulation.\n\nPhase II (System Calibration):\n\nBCI-SCS synchronization: Calibration of decoded motor intent to trigger SCS parameters.\n\nSCS-EXO synchronization: Integration of SCS pulses with exoskeleton-assisted gait training.\n\nPhase III (Rehabilitation):\n\nDaily BCI-SCS-EXS training sessions (60 minutes, 5 times\u002Fweek for 1 year). Adaptive adjustments to stimulation parameters and exoskeleton support based on performance.\n\nRemote monitoring of device performance and emergency intervention for technical issues.\n\nOutcome Measures:\n\nPrimary: Safety (adverse events, device performance, synchronization metrics). Secondary: Efficacy (motor function, neurophysiological function, quality of life).\n\nEthics and Safety:\n\nInformed consent will be obtained from all participants. Adverse events will be monitored and reported according to CTCAE 5.0 guidelines.\n\nParticipant confidentiality will be strictly maintained. This study will provide foundational evidence for the safety and feasibility of the BCI-SCS-EXO system, paving the way for future randomized controlled trials in SCI rehabilitation.",[89,90,91,92,93,94,95,24,96,97],"Spinal Cord Injuries (SCI)","Spinal Cord Injury, Chronic","Spinal Cord Injury","Spinal Cord Injury Cervical","Spinal Cord Injury Thoracic","Spinal Cord Injury (Quadraplegia)","Motor Impairment","Gait Training","Gait Impairment",[99,100,101,102,103,104,105,106,107,108,109,110],"Brain-computer interface","Spianl cord stimulation","Exoskeleton","Rehabilitation","Spinal cord injury","Motor dysfunction","BCI","Brain-spinal interface","BSI","Brain-machine interface","Gait training","Neural plasticity","2025-05-14",{"date":63,"type":40},{"date":114,"type":40},"2025-04-23",{"date":116,"type":19},"2027-04-30",{"name":118,"class":47},"Xuanwu Hospital, Beijing",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":84,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":72},"100579272","effect-of-vagus-nerve-stimulation-via-the-outer-ear-on-motor-and-cognitive-deficits-after-ischemic-stroke-100579272","NCT06822140","Effect of Vagus Nerve Stimulation Via the Outer Ear on Motor and Cognitive Deficits After Ischemic Stroke","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Motor and Cognitive Deficits After Ischemic Stroke","EVAMOS","Inclusion Criteria:\n\n* Onset of stroke ≥15 days and ≤30 days after randomization\n* Ischemic stroke in the anterior cerebral circulation detected by MR imaging or computer tomography\n* National Institutes of Health Stroke Scale (NIHSS) score ≥3 points\n* Montreal Cognitive Assessment (MoCA) score ≤ 26 points\n* First ever stroke\n* Right-handed\n* Ability to participate in a standardized rehabilitation therapy\n* Written informed consent signed by the subject or next kin\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant and breastfeeding women\n* Severe concomitant neurological (brain tumor, encephalitis, Parkinson disease, epilepsy prior to stroke onset) or mental disorders (psychiatric conditions such as schizophrenia, uncontrolled depression or bipolar disorder before stroke onset)\n* Severe aphasia (i.e. unable to follow two-stage-commands)\n* Pre-existing hemiparesis\n* Documented history of dementia before index stroke\n* Primary intracranial hematoma or subarachnoid hemorrhage\n* Active implantable medical device (e.g., pacemaker, deep brain stimulator, cochlear implants, cerebral shunts)\n* Metal cervical spine hardware or metallic implant near the stimulation site\n* Modified Rankin scale (mRS) ≥ 2 prior to stroke onset\n* Low heart rate (\\\u003C 60 bpm)\n* Severe vision and hearing problems\n* Alcohol and drug abuse\n* Active post-stroke delirium, unable to cooperate\n* Type 1 and 2 diabetes mellitus\n* Sore and diseased skin of the auricle\n* Patients receiving any therapy (medication or otherwise) at study entry that would interfere with VNS",{"count":128,"type":19},144,[86],"The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to treat motor and neurocognitive deficits after ischemic stroke when applied within 30 days after onset of stroke.\n\nThe main questions it aims to answer are:\n\n* Does tVNS improve motor deficits measured by the Fugl-Mayer assessment after ischemic stroke?\n* Does tVNS ameliorate stroke-related cognitive impairment? Researchers will compare tVNS to a placebo (sham stimulation, i.e. an electrode is fixed on the ear without applying electrical impulses ) to see if tVNS works to treat motor and cognitive deficits after stroke .\n\nParticipants will:\n\n* Receive tVNS or sham stimulation for 30 minutes 5 days a week during 5 weeks after ischemic stroke\n* Receive smotor and cognitive training during the tVNS or sham stimulation\n* Will take part on a standardized stroke rehabilitation program during the 5 weeks in a rehabilitation clinic.",[132,24,133,134],"Ischemic Stroke","Cognitive Impairment","Vagus Nerve Stimulation","NOT_YET_RECRUITING","2025-02-16",{"date":138,"type":40},"2025-02-19",{"date":140,"type":19},"2025-04-01",{"date":142,"type":19},"2028-04-30",{"name":144,"class":47},"Rheinburg-Klinik",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":84,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":72},"100579117","isolated-versus-combined-cognitive-and-motor-high-tech-rehabilitation-100579117","NCT06820125","Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation","Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation in Patients with Multiple Sclerosis","Inclusion Criteria:\n\n* presence of mild (one or two neuropsychological tests below the cut-off score, 5th percentile) or severe (more than two neuropsychological tests below the cut-off score, 5th percentile) cognitive impairment,\n* mild to moderate walking disability with Expanded Disability Status Scale (EDSS) between 3 and 6,\n* no relapse or associated steroid use in the past three months,\n* adequate visual and auditory capacity to operate computer software.\n\nExclusion Criteria:\n\n* presence of other neurological disorders than MS,\n* major psychiatric disorders,\n* high levels of anxiety and\u002For depression (score\\>20 for Depression scale and up to 14 for Anxiety scale on Italian adaptation of the Depression, Anxiety and Stress Scale (DASS-21),\n* substance abuse,\n* any type of rehabilitation intervention in the month prior to recruitment\n* pharmacological therapy not well defined and\u002For changed during the study\n* presence of paroxysmal vertigo\n* lower limb botulinum toxin injections within the previous 12 weeks",{"count":153,"type":19},48,[86],"The first aim of this project is to investigate the effects of different high-tech neurorehabilitation interventions (cognitive, motor, and combined cognitive-motor) on both cognitive and motor disability outcomes in people with multiple sclerosis (MS).\n\nThe second aim is to identify the cognitive and motor profiles of MS patients who benefit the most from either the combined cognitive-motor rehabilitation intervention or the isolated cognitive or motor treatments.",[102,157,158,24],"Multiple Sclerosis","Cognitive Deficit",[160,161,162,163],"rehabilitation","multiple sclerosis","cognitive deficits","motor deficits","2025-02-05",{"date":166,"type":40},"2025-02-11",{"date":168,"type":40},"2023-07-05",{"date":170,"type":19},"2026-07-05",{"name":172,"class":47},"Universita di Verona"]